Details of the Drug
General Information of Drug (ID: DMYRLA0)
Drug Name |
ZARAGOZIC ACID B
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Zaragozic acid B; UNII-2AF560R2HC; 2AF560R2HC; CHEMBL504845; 146389-61-9; SCHEMBL6130350; GTPL6061; BDBM50292415; L-glycero-D-altro-Pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-(6,12-tetradecadienoate), (5(6E,12E),7S,10xi,11xi,12xi)-; (1R,2S,3S,5S,6R,7R)-2,6-dihydroxy-5-[(E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-7-[(6E,12E)-tetradeca-6,12-dienoyl]oxy-4,8-dioxabicyclo[3.2.1]octane-1,2,3-tricarboxylic acid
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 730.8 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 23 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 6 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 13 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References